Morgan Stanley upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from an equal weight rating to an overweight rating in a report published on Monday, Marketbeat Ratings reports. The firm currently has $27.00 price target on the stock, up from their prior price target of $20.00.
A number of other research analysts also recently issued reports on TEVA. Oppenheimer reissued a hold rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, November 1st. Royal Bank of Canada set a $22.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a hold rating in a research report on Friday. Bank of America boosted their price objective on shares of Teva Pharmaceutical Industries from $19.00 to $20.00 and gave the company an underperform rating in a research report on Friday. Cantor Fitzgerald set a $25.00 price objective on shares of Teva Pharmaceutical Industries and gave the company a hold rating in a research report on Friday, July 13th. Finally, Maxim Group reissued a hold rating on shares of Teva Pharmaceutical Industries in a research report on Thursday, November 1st. Five equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $21.58.
NYSE:TEVA opened at $22.85 on Monday. Teva Pharmaceutical Industries has a 52 week low of $11.41 and a 52 week high of $25.96. The company has a debt-to-equity ratio of 1.75, a current ratio of 0.94 and a quick ratio of 0.61. The firm has a market cap of $22.97 billion, a P/E ratio of 5.81, a PEG ratio of 1.85 and a beta of 0.77.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Thursday, November 1st. The company reported $0.64 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.11. The business had revenue of $4.53 billion for the quarter, compared to the consensus estimate of $4.54 billion. Teva Pharmaceutical Industries had a negative net margin of 54.67% and a positive return on equity of 21.83%. The company’s quarterly revenue was down 19.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.00 EPS. Equities research analysts expect that Teva Pharmaceutical Industries will post 2.72 EPS for the current fiscal year.
In related news, insider Deborah A. Griffin sold 2,376 shares of the stock in a transaction dated Tuesday, September 18th. The shares were sold at an average price of $23.71, for a total transaction of $56,334.96. Following the sale, the insider now directly owns 2,376 shares of the company’s stock, valued at approximately $56,334.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Iris Beck Codner sold 4,165 shares of the stock in a transaction dated Thursday, August 9th. The shares were sold at an average price of $22.70, for a total transaction of $94,545.50. Following the sale, the executive vice president now directly owns 8,290 shares in the company, valued at $188,183. The disclosure for this sale can be found here. Insiders sold a total of 10,350 shares of company stock worth $239,430 over the last ninety days. Insiders own 0.43% of the company’s stock.
A number of hedge funds have recently made changes to their positions in TEVA. CWM LLC grew its position in Teva Pharmaceutical Industries by 315,000.0% during the 3rd quarter. CWM LLC now owns 6,302 shares of the company’s stock valued at $136,000 after purchasing an additional 6,300 shares during the last quarter. Wealthstreet Investment Advisors LLC purchased a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at about $200,000. MAI Capital Management purchased a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at about $204,000. FNY Investment Advisers LLC grew its position in Teva Pharmaceutical Industries by 989,900.0% during the 3rd quarter. FNY Investment Advisers LLC now owns 9,900 shares of the company’s stock valued at $213,000 after purchasing an additional 9,899 shares during the last quarter. Finally, Greenleaf Trust purchased a new stake in Teva Pharmaceutical Industries during the 2nd quarter valued at about $215,000. 65.10% of the stock is currently owned by institutional investors.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
See Also: Growth Stocks, What They Are, What They Are Not
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.